MIC-Lx is under clinical development by TolerogenixX and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIC-Lx’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MIC-Lx overview

MIC-Lx is under investigation for the treatment of multiple sclerosis (MS), kidney transplant rejection and systemic lupus erythematosus (SLE). It is administered through intravenous route.

TolerogenixX overview

TolerogenixX is a biotechnology company that develops patented and clinically tested alternative cell therapy technique for individualised immunosuppression to treat post-transplant patients and those suffering from numerous autoimmune diseases. The company offers TolerogenixX technology which is tailored immunosuppressive therapy by the production of tolerogenic mitomycin C-treated peripheral blood mononuclear cells (MIC) cells through incubation of specific white blood cells with the antiproliferative substance Mitomycin C. The company conducts its phase I clinical trial on kidney transplantation and renal transplantation. It’s therapy is supplied in a kit, finds application in any hospital across the globe for the treatment of organ transplant recipients and various autoimmune diseases. TolerogenixX is headquartered in Heidelberg, Germany.

For a complete picture of MIC-Lx’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.